Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
Gynecol Oncol
; 164(2): 406-414, 2022 02.
Article
em En
| MEDLINE
| ID: mdl-34844775
ABSTRACT
OBJECTIVE:
To estimate the cost-effectiveness of olaparib after being funded by the Spanish National Health Service (SNHS) as first-line monotherapy maintenance treatment in patients with advanced high-grade serous ovarian carcinoma (HGSOC) and BRCA mutations in Spain.METHODS:
A semi-Markov model with one-month cycles was adapted to the Spanish healthcare setting, using the perspective of the SNHS, and a time horizon of 50 years. Two scenarios were compared receiving olaparib vs. no maintenance treatment. The model comprised four health states and included the clinical results of the SOLO1 study, along with the direct healthcare costs associated with the use of first-line and subsequent treatment resources (2020 ). A discount rate of 3% was applied for future cost and quality-of-life outcomes. A probabilistic sensitivity analysis (PSA) was also carried out and a cost-effectiveness threshold of 25,000 per quality adjusted life year (QALY) was considered.RESULTS:
The introduction of olaparib as a first-line maintenance treatment for advanced HGSOC patients with BRCA mutations implied a cost of 131,614.98 compared to 102,369.54 without olaparib (difference 29,245.44), with an improvement of 2.00 QALYs (5.56 and 3.57, respectively). Therefore, olaparib is cost-effective for advanced HGSOC patients with BRCA mutations, with an incremental cost-effectiveness ratio of 14,653.2/QALY. The results from the PSA showed that 92.1% of the simulations fell below the 25,000/QALY threshold. The model showed that olaparib could improve the overall survival by 2 years, vs. no maintenance treatment.CONCLUSIONS:
Olaparib as first-line maintenance treatment is cost-effective in advanced HGSOC patients with BRCA mutations in Spain.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Ftalazinas
/
Piperazinas
/
Anos de Vida Ajustados por Qualidade de Vida
/
Genes BRCA1
/
Genes BRCA2
/
Inibidores de Poli(ADP-Ribose) Polimerases
/
Carcinoma Epitelial do Ovário
Tipo de estudo:
Clinical_trials
/
Health_economic_evaluation
/
Prognostic_studies
Aspecto:
Patient_preference
Limite:
Aged
/
Female
/
Humans
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Gynecol Oncol
Ano de publicação:
2022
Tipo de documento:
Article